Solid organ transplantation has developed immeasurably over the last two decades. Even in relatively recent times such as the mid 1970's, transplantation was regarded as an experimental modality of treatment rather than an established clinical tool. Since then the speciality has risen from the roles of experiment so that transplantation of kidney, heart, liver, lung, pancreas and even small bowel has now become relatively commonplace. Ten to fifteen years ago, the one year graft survival for renal transplantation was not much greater than 50%. The single most common cause of early graft loss was acute rejection which was regarded as the "sword of Damocles" of transplantation. In the majority of cases acute rejection of transplants is no longer the scourge that it used to be. The purpose of this article is to briefly review current thoughts on the management of acute and chronic rejection and the role of new immunosuppressive agents in transplantation.
在过去二十年中,实体器官移植取得了巨大发展。即使在相对较近的时期,比如20世纪70年代中期,移植还被视为一种试验性治疗方式,而非成熟的临床手段。从那时起,该专业已从试验阶段发展起来,如今肾脏、心脏、肝脏、肺、胰腺甚至小肠移植都已相对常见。十年到十五年前,肾移植的一年移植物存活率仅略高于50%。早期移植物丢失最常见的单一原因是急性排斥反应,它曾被视为移植领域的“达摩克利斯之剑”。在大多数情况下,移植的急性排斥反应已不再像过去那样是一场灾难。本文旨在简要回顾当前关于急性和慢性排斥反应管理的观点,以及新型免疫抑制剂在移植中的作用。